GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ResMed Inc (FRA:RME) » Definitions » Cyclically Adjusted PS Ratio

ResMed (FRA:RME) Cyclically Adjusted PS Ratio : 9.57 (As of May. 22, 2024)


View and export this data going back to 1995. Start your Free Trial

What is ResMed Cyclically Adjusted PS Ratio?

As of today (2024-05-22), ResMed's current share price is €201.00. ResMed's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €21.01. ResMed's Cyclically Adjusted PS Ratio for today is 9.57.

The historical rank and industry rank for ResMed's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:RME' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 6.12   Med: 8.65   Max: 18.37
Current: 9.56

During the past years, ResMed's highest Cyclically Adjusted PS Ratio was 18.37. The lowest was 6.12. And the median was 8.65.

FRA:RME's Cyclically Adjusted PS Ratio is ranked worse than
85.47% of 475 companies
in the Medical Devices & Instruments industry
Industry Median: 2.2 vs FRA:RME: 9.56

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

ResMed's adjusted revenue per share data for the three months ended in Mar. 2024 was €7.468. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €21.01 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


ResMed Cyclically Adjusted PS Ratio Historical Data

The historical data trend for ResMed's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ResMed Cyclically Adjusted PS Ratio Chart

ResMed Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.54 13.65 15.31 11.09 10.40

ResMed Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.73 10.40 6.84 7.82 8.67

Competitive Comparison of ResMed's Cyclically Adjusted PS Ratio

For the Medical Instruments & Supplies subindustry, ResMed's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ResMed's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ResMed's Cyclically Adjusted PS Ratio falls into.



ResMed Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

ResMed's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=201.00/21.01
=9.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ResMed's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, ResMed's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=7.468/131.7762*131.7762
=7.468

Current CPI (Mar. 2024) = 131.7762.

ResMed Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 2.135 100.560 2.798
201409 2.069 100.428 2.715
201412 2.412 99.070 3.208
201503 2.734 99.621 3.616
201506 2.825 100.684 3.697
201509 2.578 100.392 3.384
201512 2.950 99.792 3.895
201603 2.886 100.470 3.785
201606 3.258 101.688 4.222
201609 2.919 101.861 3.776
201612 3.539 101.863 4.578
201703 3.369 102.862 4.316
201706 3.471 103.349 4.426
201709 3.062 104.136 3.875
201712 3.532 104.011 4.475
201803 3.332 105.290 4.170
201806 3.700 106.317 4.586
201809 3.500 106.507 4.330
201812 3.965 105.998 4.929
201903 4.061 107.251 4.990
201906 4.306 108.070 5.251
201909 4.262 108.329 5.184
201912 4.551 108.420 5.531
202003 4.780 108.902 5.784
202006 4.681 108.767 5.671
202009 4.370 109.815 5.244
202012 4.491 109.897 5.385
202103 4.438 111.754 5.233
202106 4.959 114.631 5.701
202109 5.232 115.734 5.957
202112 5.386 117.630 6.034
202203 5.341 121.301 5.802
202206 5.884 125.017 6.202
202209 6.523 125.227 6.864
202212 6.620 125.222 6.967
202303 7.077 127.348 7.323
202306 7.016 128.729 7.182
202309 7.003 129.860 7.106
202312 7.227 129.419 7.359
202403 7.468 131.776 7.468

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ResMed  (FRA:RME) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


ResMed Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of ResMed's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ResMed (FRA:RME) Business Description

Address
9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

ResMed (FRA:RME) Headlines

No Headlines